Bracebridge Capital LLC Acquires 30,645 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Bracebridge Capital LLC grew its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 7.2% in the 4th quarter, HoldingsChannel reports. The firm owned 459,216 shares of the company’s stock after acquiring an additional 30,645 shares during the quarter. Aquestive Therapeutics accounts for approximately 0.1% of Bracebridge Capital LLC’s investment portfolio, making the stock its 18th biggest holding. Bracebridge Capital LLC’s holdings in Aquestive Therapeutics were worth $1,635,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Stifel Financial Corp lifted its position in Aquestive Therapeutics by 315.4% in the 4th quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock worth $1,419,000 after buying an additional 302,617 shares during the last quarter. MetLife Investment Management LLC lifted its position in Aquestive Therapeutics by 11.4% during the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock valued at $143,000 after acquiring an additional 4,125 shares during the period. Marshall Wace LLP purchased a new stake in shares of Aquestive Therapeutics in the 4th quarter worth approximately $198,000. Barclays PLC raised its holdings in Aquestive Therapeutics by 19.5% in the fourth quarter. Barclays PLC now owns 118,711 shares of the company’s stock worth $422,000 after buying an additional 19,399 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics during the 4th quarter valued at $498,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Trading Up 2.8 %

Shares of NASDAQ:AQST opened at $2.58 on Tuesday. Aquestive Therapeutics, Inc. has a twelve month low of $2.20 and a twelve month high of $5.80. The company has a market capitalization of $255.09 million, a PE ratio of -5.73 and a beta of 2.59. The firm has a 50 day simple moving average of $2.82 and a 200-day simple moving average of $3.66.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. As a group, equities research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AQST shares. Lake Street Capital dropped their price target on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Wednesday, April 2nd. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.67.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.